Sign in
CompletedNo phase

Dual-Task Cost in Bilateral Hearing Loss

Key facts

Who runs it
New York University
Where
New York, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
67 people enrolled
Started
1 Feb 2022
Ended
22 Nov 2024
Type of study
Observational, 3 groups
Treatments tested
  • Gait assessment
  • Cognitive assessment
Record updated
13 January 2025

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate which is defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear
  • Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderately-severe which is defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear
  • Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical severe which is defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear
  • Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical profound which is defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear
  • No asymmetry of HL which is defined as a difference in PTA that is greater than 15 dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears
  • Adults aged 40 and older with normal hearing which is defined as a PTA below 25dB (0.5-4 kHz) bilaterally
  • Subjects above 65 years of age, with symmetric ARHL in the high frequencies (>3K), with unaided PTA < 40 dB (0.5-4KHz) will be included in the control group as well

Who cannot take part

  • Take medications that might influence gait or balance (e.g., methylphenidate)
  • Visual impairment above 20/63 (NYS Department of Motor Vehicle cutoff for driving) on the Early Treatment Diabetic Retinopathy Study (ETDRS) Acuity Test that cannot be corrected with lenses
  • Any neurological condition interfering with balance or walking (e.g. multiple sclerosis, Parkinson's disease, stroke)
  • Currently seeking medical care for another orthopaedic condition or vestibular rehabilitation
  • A medical diagnosis of peripheral neuropathy
  • Lack of protective sensation based on the Semmes-Weinstein 5.07 Monofilament Test
  • Active complaint of dizziness
  • Conductive HL or air bone gap
  • A recent onset of a sudden HL
  • Pregnancy
  • Acute musculoskeletal pain at time of testing
  • Inability to read an informed consent form in English

Where in United States

  • New York Eye and Ear Infirmary of Mount SinaiNew York, United States
  • New York University Physical Therapy DepartmentNew York, United States

About the trial

What the trial wants to find out

The specific aims of the research study are:

Read full original descriptionShow less

1. Compare single-task gait parameters between individuals with hearing loss (HL) and age and education matched controls with normal hearing [normal vs moderate-profound hearing loss (N=23 for each group)]. For that we will compare the primary outcome measure, gait speed, between the groups while participants are walking at a comfortable speed for 1 minute. 2. Compare cognitive function between individuals with HL and age and education matched controls. For that we will compare the Neurocognitive Index, derived from a cognitive assessment between groups. 3. Compare the effect of a cognitive task while walking on gait parameters between people with HL and age education matched controls with normal hearing. For that we will compare the primary outcome measure, gait speed, between groups while participants are walking at a comfortable speed and counting backwards [serial subtraction of 3] for 1 minute. 4. Explore whether cognitive performance (i.e., the Neurocognitive Index) is correlated with Dual task cost (DTC), a deterioration of gait speed while walking and performing concurrent cognitive task [serial subtraction of 3]. The formula to calculate this is the following: DTC = 100 X [(DT - single task)/ single task].

The 3 groups in the trial

  • Control participants with normal hearing.

    Adults aged 40 and older with normal hearing will be defined as a PTA below 25dB (0.5-4 kHz) bilaterally.

    Treatment: Gait assessment and Cognitive assessment

  • Mild Bilateral Symmetrical Hearing Loss

    Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical mild HL in the past three month and on will be defined as a PTA between 26-40dB HL (0.5-4 kHz) in the better ear.

    Treatment: Gait assessment and Cognitive assessment

  • >Moderate Bilateral Symmetrical Hearing Loss

    Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate, moderately-severe, severe, or profound sensorineural HL in the past three month and on. Moderate hearing will be defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear, moderately-severe hearing will be defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear, severe HL will be defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear and profound HL will be defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear. Asymmetry of HL will be defined as a difference in PTA that is greater than dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears.

    Treatment: Gait assessment and Cognitive assessment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dual-Task Cost During Walking in People With Hearing Loss Compared to Normal Hearing
Record updated
13 January 2025